Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Millions of Americans have already received two COVID-19 vaccine shots. However, there s a possibility that a third booster dose will be needed. In this
Motley Fool Live video
recorded on May 17, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Motley Fool contributor Keith Speights discuss when we ll know if a booster shot will be required or not.
Corinne Cardina: Let s talk about the future of booster shots speaking of making a lot of money in the long run. What should investors know? What s the latest in terms of when are we going to know when we ll need more shots, whether it s a year out. Tell me about that.
Author Bio
Taylor Carmichael is a former attorney and filmmaker. He s the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.
In December, the Food and Drug Administration (FDA) gave emergency use authorizations (EUA) to the mRNA vaccines from
Pfizer (NYSE:PFE). Since then, the two companies have seized the lion share of the vaccine market in the U.S.
Meanwhile, the
Novavax (NASDAQ:NVAX) vaccine has been delayed, and the company now hopes that it will receive an EUA in July. Will there be any vaccine market left for the biotech upstart? In this clip from
3 Unstoppable Healthcare Stocks to Buy on the Dip fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Taylor Carmichael is a former attorney and filmmaker. He s the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.
OptimizeRx (NASDAQ:OPRX) is a small cap with a big future. The company is reimagining the process for how drugs are marketed to physicians. Because of the COVID-19 lockdown, internet sales are really jumping, with revenue escalating 110% in the most recent quarter. In this clip, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool contributor Taylor Carmichael discuss OptimizeRx stock. This segment was
Author Bio
Taylor Carmichael is a former attorney and filmmaker. He s the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.
Teladoc Health (NYSE:TDOC) is the top dog and first mover in moving doctor visits to the internet. It s a huge market opportunity, and rivals will no doubt try to take market share. Does Teladoc have a moat? What does the competitive landscape look like? Healthcare and Cannabis Bureau Chief Corinne Cardina and Motley Fool contributor Taylor Carmichael discuss possible possible rivals to Teladoc Health. This segment was